

Netrin‐1 expression is upregulated in hepatic stellate cells (HSCs) during metabolic dysfunction–associated steatohepatitis and injury‐mediated liver fibrosis. Secreted Netrin‐1 establishes an autocrine positive feedback loop by binding to UNC5B receptors on HSCs. Receptor activation triggers calcium influx and profibrotic response in HSCs, leading to increased extracellular matrix (ECM) production and liver fibrosis. ABSTRACT Liver fibrosis is a central feature of progressive liver diseases, including metabolic dysfunction‐associated steatohepatitis (MASH). The profibrotic liver microenvironment drives hepatic stellate cell (HSC) activation and collagen deposition. However, the nature of HSC‐mediated autocrine signaling during the fibrotic response has not been completely characterized. Here, we identify Netrin‐1 as an autocrine factor that drives HSC activation and liver fibrosis in patients with MASH. Hepatic Netrin‐1 expression was consistently elevated across multiple experimental models of liver fibrosis. Functional studies showed that adenovirus‐associated virus (AAV)‐mediated hepatic Netrin‐1 overexpression exacerbated fibrosis, whereas HSC‐specific conditional ablation of Netrin‐1 markedly attenuated diet‐induced MASH and CCl4‐induced liver fibrosis. Notably, lipid nanoparticle‐mediated siRNA knockdown of Netrin‐1 ameliorated liver fibrosis in mice. Mechanistic investigations revealed that Netrin‐1 promotes HSC activation through autocrine signaling mediated by the UNC5B receptor, which triggers rapid intracellular Ca2+ mobilization and downstream SMAD2 phosphorylation and fibrogenic gene expression. Collectively, our findings identify a novel autocrine signaling axis in which HSC‐derived Netrin‐1 establishes a positive feedback loop that sustains HSC activation and drives fibrotic progression. Blocking the Netrin‐1‐mediated fibrogenic response may offer a potential therapeutic strategy for anti‐fibrotic interventions. Netrin-1 expression is upregulated in hepatic stellate cells (HSCs) during metabolic dysfunction–associated steatohepatitis and injury-mediated liver fibrosis. Secreted Netrin-1 establishes an autocrine positive feedback loop by binding to UNC5B receptors on HSCs. Receptor activation triggers calcium influx and profibrotic response in HSCs, leading to increased extracellular matrix (ECM) production and liver fibrosis. ABSTRACT Liver fibrosis is a central feature of progressive liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The profibrotic liver microenvironment drives hepatic stellate cell (HSC) activation and collagen deposition. However, the nature of HSC-mediated autocrine signaling during the fibrotic response has not been completely characterized. Here, we identify Netrin-1 as an autocrine factor that drives HSC activation and liver fibrosis in patients with MASH. Hepatic Netrin-1 expression was consistently elevated across multiple experimental models of liver fibrosis. Functional studies showed that adenovirus-associated virus (AAV)-mediated hepatic Netrin-1 overexpression exacerbated fibrosis, whereas HSC-specific conditional ablation of Netrin-1 markedly attenuated diet-induced MASH and CCl4-induced liver fibrosis. Notably, lipid nanoparticle-mediated siRNA knockdown of Netrin-1 ameliorated liver fibrosis in mice. Mechanistic investigations revealed that Netrin-1 promotes HSC activation through autocrine signaling mediated by the UNC5B receptor, which triggers rapid intracellular Ca 2+ mobilization and downstream SMAD2 phosphorylation and fibrogenic gene expression. Collectively, our findings identify a novel autocrine signaling axis in which HSC-derived Netrin-1 establishes a positive feedback loop that sustains HSC activation and drives fibrotic progression. Blocking the Netrin-1-mediated fibrogenic response may offer a potential therapeutic strategy for anti-fibrotic interventions. Advanced Science, EarlyView.
Medical Journal
|15th Jan, 2026
|Nature Medicine's Advance Online Publication (AOP) table of contents.
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley